بنیاد تومور کودکان http://www.ctf.org
بنیاد تومور کودکان http://www.ctf.org
دارای امتیاز بازاموزی نیست، برای سطح تخصصی برگزار می شود. حامی این کنفرانس بنیاد غیرانتفاعی تومور کودکان است. زمان برگزاری: شنبه هشتم ژوئن 2013 تا سه شنبه یازدهم ژوئن مکان: Monterey, Californiaمحل برگزاری کنفرانس: Portola Hotel & SpaTwo Portola Plazaسخنرانان مدعو: ..........جایزه مخصوص ون رکلینگ هازن: مهلت ارسال تا اول می 2013 - شامل کسانی است که بیشترین اثرگذاری را در خصوص این بیماری داشته اند.
مهلت ارسال چکیده مقاله: 22 مارس 2013امروز هیجدهم مارس است.هزینه ثبت نام Early Bird Special: Register by April 26, 2013 - $300 USDRegular Deadline: Register by May 31, 2013 - $350 USDOn-Site Registration: Register between June 7-11, 2013 - $400 USD
تهیه چکیده با شرایط زیر
All text should be in 12-point Arial font
Abstracts SHOULD NOT EXCEED 400 WORDS or ONE PAGE
including author & affiliation information, and references
Provide the presenting author, affiliation and abstract title as follows on the top left of the abstract, bolded
Title of Abstract: Bold Text Presenting Author (including degree, MD,
PhD,etc.): Bold Text Institution/University: Regular Font, Italicize
List all additional authors on the bottom after the abstract text:
e.g., Full List Authors: Joe Blogs MD, University of Tumors; Jane
White Ph.D.,George Washington University, John Smith MD, Ph.D.,
Institute of Medical Research, Mary Lee, MD, Jones University
Where scientific abbreviations are used, please include the full
wording the first time this is used and the abbreviation thereafter. Please do not include Greek or other symbols but use the longhand version of the word (e.g., alpha, beta, delta).
Please indicate the granting agency and mechanism whose fiscal support
made the research possible at the end of the abstract. The Name of file should be labeled with the presenting author’s name as follows: Last Name, First NameIf abstracts received do not meet the above requirements, CTF reserves the right to disqualify any abstract.Poster Format: The dimensions of all posters should be 4 ft. H X 6 ft. L Please note that your poster may not exceed these dimensions. Pushpins will be available.Abstract Selection Procedure
The Conference Chairs along with session chairs will select the
submitted abstracts and designate them to the appropriate session.
Submitters will be notified of acceptance by mid-April 2013.
Acceptance as a platform or poster presenter for the 2013 NF Conference
does not cover the cost of travel to the meeting, registration for the
conference, or printing of poster materials. Please note that by
submitting an abstract, the submitter agrees to attend the meeting and
present the poster or take part in the oral presentations. Abstract
presenters must register in full to attend the meeting. All
abstracts accepted for the 2013 NF Conference will be printed in a
Program and Abstract Book for distribution to meeting attendees. The Program and Abstract Book will be made available online in early June, prior to the 2013 NF Conference.
A meeting report after the Conference for publication in Children's
Tumor Foundation quarterly NF newsletter and Research E-NewsBlast.
If your presentation or poster is mentioned in this report you will
have the opportunity to review and request edits to this information
prior to report publication. Your abstract, poster and
presentation at the NF Conference constitute public disclosure. For more
information on public disclosure as it relates to future publications
& patent filings from your research, you may wish to speak with your
institution’s Technology Transfer/Patenting & Licensing Office.Abstract Submission Policy & Guidelines StatementThere
is no limit on the number of abstracts an individual may submit.
Abstracts should be submitted with the intention that they will be
presented if selected. Do not submit an abstract if you will not attend
the meeting. The Abstract Submission Policy & Guidelines are
intended to: Ensure that the Children’s Tumor Foundation is
able to report to our constituents (those with NF, their families, our
donors, and the larger scientific & medical community who may be
unable to attend the NF Conference) on progress highlights reported at
the NF Conference, and Provide those investigators who are
presenting data at the NF Conference with an opportunity to specify what
information from their presentations they are comfortable having
disclosed and distributed in any public reports of the NF Conference
emerging from the Foundation for the above purpose